Live tape
Top 8, mentions 7d10,375TSLA2,414 mentions▲ +0.06SPCX1,882 mentions▲ +0.08GOOGL1,298 mentions▲ +0.04CRWV1,186 mentions▲ +0.04NVDA1,045 mentions▲ +0.07QQQ1,009 mentions▲ +0.05META776 mentions▲ +0.05NBIS765 mentions▲ +0.07

Equity · Healthcare

BIO

NYSE

Bio-Rad Laboratories (BIO)

$353 −0.21% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 19, 2026
Price · Chart
62 sessions
$400 $300 23 Jul 19 Oct

The line runs $316 on 23 July through $353 on 19 October, on a scale from $300 to $400. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 62 sessions, 23 Jul – 19 Oct 2026
Market cap $9.5B
P/E (TTM) 43.1
52-week range $242 – $390.31
Avg volume 17.6K

as of Oct 19, 2026

Bio-Rad Laboratories (BIO) reported financials

SEC EDGAR XBRL SEC EDGAR

Bio-Rad Laboratories reported revenue of $2.6B for the fiscal year ended 31 Dec 2025. Net income over the same period was $759.9M.

Figure Reported Period
Revenue $2.6B 31 Dec 2025 fiscal year
Net income $759.9M 31 Dec 2025 fiscal year
Diluted EPS $27.85 31 Dec 2025 fiscal year
Total assets $10.3B 30 Jun 2026 at period end
Total equity $7.2B 30 Jun 2026 at period end

Bio-Rad Laboratories (BIO) earnings

SEC EDGAR

Bio-Rad Laboratories last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $13.85; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 $13.85 $651M
31 Mar 2026 Q1 2026 −$19.55 $592M
31 Dec 2025 FY 2025 $27.85 $2.58B
30 Sep 2025 Q3 2025 −$12.70 $653M
30 Jun 2025 Q2 2025 $11.67 $652M
31 Mar 2025 Q1 2025 $2.29 $585M
31 Dec 2024 FY 2025 −$25.57 $2.57B
30 Sep 2024 Q3 2024 $23.34 $650M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Bio-Rad Laboratories (BIO) institutional holders (13F)

SEC Form 13F SEC EDGAR

10 of the 45 institutional funds we track reported a Bio-Rad Laboratories position for the quarter ended 30 Jun 2026 — a combined $155.7M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Added +103.8% shares 192,711 $56.0M
Fisher Asset Management Held (±25%) −1.5% shares 116,909 $34.3M
Citadel Advisors Trimmed −59.1% shares 60,819 $17.9M
Millennium Management Added +1,718.3% shares 59,895 $17.6M
GAMCO Investors Held (±25%) 26,750 $7.9M
Tudor Investment Corp Added +384.4% shares 25,000 $7.3M
D. E. Shaw & Co. Added +136.4% shares 19,256 $5.7M
Marshall Wace Trimmed −42.9% shares 18,980 $5.6M
Two Sigma Investments Held (±25%) −6.1% shares 10,320 $3.0M
Man Group Trimmed −97.9% shares 1,437 $422K

Bio-Rad Laboratories (BIO) fails-to-deliver

SEC CNS data SEC

On 22 Sep 2026, 451 shares of Bio-Rad Laboratories failed to deliver (about $170K).

Settlement date Shares failed Notional % of shares out
22 Sep 2026 451 $170K 0.002%
14 Sep 2026 400 $148K 0.001%
10 Sep 2026 2,061 $777K 0.008%
08 Sep 2026 3 $1K <0.001%

Congressional trades in Bio-Rad Laboratories (BIO)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Bio-Rad Laboratories is a sale by Lois Frankel (house, FL), dated 08 Sep 2023.

Date Member Type Amount
08 Sep 2023 filed 10 Oct 2023 Lois Frankel house · Democrat–FL Sale $1K–$15K
29 Jun 2023 filed 28 Jul 2023 Lois Frankel house · Democrat–FL Purchase $1K–$15K
28 Jun 2023 filed 28 Jul 2023 Lois Frankel house · Democrat–FL Purchase $1K–$15K
30 Nov 2022 filed 29 Dec 2022 Susie Lee house · Democrat–NV Sale $1K–$15K
05 Jan 2021 filed 10 Feb 2021 Susie Lee house · Democrat–NV Sale $1K–$15K
02 Oct 2020 filed 08 Dec 2020 Susie Lee house · Democrat–NV Sale $1K–$15K
27 May 2020 filed 15 Jun 2020 Susie Lee house · Democrat–NV Sale $1K–$15K

Bio-Rad Laboratories (BIO): frequently asked questions

From live data

How many institutions hold Bio-Rad Laboratories?

10 of the 45 institutional funds we track reported a Bio-Rad Laboratories position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Bio-Rad Laboratories had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Bio-Rad Laboratories is dated 22 Sep 2026, when 451 shares failed to deliver.

When did Bio-Rad Laboratories last report earnings?

Bio-Rad Laboratories last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $13.85; no next date is announced in SEC filings yet.

What exchange is Bio-Rad Laboratories listed on?

Bio-Rad Laboratories trades on NYSE under the ticker BIO.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings